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Abstract
Background: Provision of routine iron supplements to prevent anaemia could increase the risk for lower genital
tract infections as virulence of some pathogens depends on iron availability. This trial in Burkina Faso assessed
whether weekly periconceptional iron supplementation increased the risk of lower genital tract infection in young
non-pregnant and pregnant women.
Methods: Genital tract infections were assessed within a double blind, controlled, non-inferiority trial of malaria risk
among nulliparous women, randomised to receive either iron and folic acid or folic acid alone, weekly, under direct
observation for 18 months. Women conceiving during this period entered the pregnancy cohort. End assessment
(FIN) for women remaining non-pregnant was at 18 months. For the pregnancy cohort, end assessment was at the
first scheduled antenatal visit (ANC1). Infection markers included Nugent scores for abnormal flora and bacterial
vaginosis (BV), T. vaginalis PCR, vaginal microbiota, reported signs and symptoms, and antibiotic and anti-fungal
prescriptions. Iron biomarkers were assessed at baseline, FIN and ANC1. Analysis compared outcomes by intention
to treat and in iron replete/deficient categories.
Results: A total of 1954 women (mean 16.8 years) were followed and 478 (24.5%) became pregnant. Median
supplement adherence was 79% (IQR 59–90%). Baseline BV prevalence was 12.3%. At FIN and ANC1 prevalence was
12.8% and 7.0%, respectively (P < 0.011). T. vaginalis prevalence was 4.9% at FIN and 12.9% at ANC1 (P < 0.001). BV
and T. vaginalis prevalence and microbiota profiles did not differ at trial end-points. Iron-supplemented non-
pregnant women received more antibiotic treatments for non-genital infections (P = 0.014; mainly gastrointestinal
infections (P = 0.005), anti-fungal treatments for genital infections (P = 0.014) and analgesics (P = 0.008). Weekly iron
did not significantly reduce iron deficiency prevalence. At baseline, iron-deficient women were more likely to have
normal vaginal flora (P = 0.016).
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Conclusions: Periconceptional weekly iron supplementation of young women did not increase the risk of lower
genital tract infections but did increase general morbidity in the non-pregnant cohort. Unabsorbed gut iron due to
malaria could induce enteric infections, accounting for the increased administration of antibiotics and antifungals in
the iron-supplemented arm. This finding reinforces concerns about routine iron supplementation in highly
malarious areas.
Trial registration: Trial registration number NCT01210040. Registered with Clinicaltrials.gov on 27 September 2010
Keywords: Lower genital tract infection, Iron, Antibiotics, Adolescents, Burkina Faso
Background
Most genital tract commensals and pathogens require iron
for growth and adhesion, including Gardnerella vaginalis
[1], Trichomonas vaginalis [2] and Candida albicans [3].
In contrast, most Lactobacillus species, which maintain a
healthy vaginal ecosystem, do not require an iron sub-
strate [4]. There have been no previous randomised trials
assessing whether vaginal infections are influenced by host
iron status. Local iron is available from secreted lactoferrin
[5], transudated ferritin and transferrin [6, 7], and men-
strual haem iron. Host iron status could affect growth and
adhesion of bacterial vaginosis (BV) [8], which is associ-
ated with a massive overgrowth of vaginal organisms. Dys-
biosis enhances human immunodeficiency viral infectivity
[9] and increases by two-fold the risk of preterm birth and
perinatal death [10]. Higher concentrations of transferrin
in cervico-vaginal fluid were correlated with preterm birth
risk in a previous study, suggesting that iron availability
must be considered [11].
In areas where anaemia is common, the World Health
Organization (WHO) recommends routine iron supple-
mentation [12]. It is currently unknown whether this affects
bacterial profiles in the reproductive tract, especially in
already iron replete women. In routine programmes, these
women receive additional supplements despite there being
good evidence that elevated iron stores predispose to sys-
temic infection and inflammation [13]. However, data are
absent regarding non-malarial infection risk following iron
supplementation during pregnancy [14], or following inter-
mittent supplementation in menstruating women [15]. In
the context of a double blind, randomised, controlled, non-
inferiority trial to assess safety of periconceptional iron sup-
plementation in relation to malaria among young women
in Burkina Faso [16], we assessed whether weekly iron sup-
plementation, or baseline host iron status, affected markers
of genital infection. The trial design provided two cohorts,
namely a large nulliparous cohort who remained non-
pregnant and received up to 18 months supplementation,
and a primigravid cohort who conceived during the trial.
Methods
The trial protocol and amendments were approved by
ethical review boards and regulatory authorities at each
collaborating centre. This sub-study was conducted
within a randomised trial of the safety of weekly iron
and folic acid supplementation in young women exposed
to malaria. The primary specified outcome was BV
prevalence, whereas the secondary outcomes were non-
BV Nugent scores, vaginal discharge and pH > 4.5. Fi-
nally, exploratory outcomes were microbiota and drug
prescriptions (antibiotics, antifungals, analgesics). Add-
itional data on the main trial and other details relevant
to this paper are provided in Additional files 1, 2, 3 and
4.
General procedures
Between April 2011 and January 2014 a randomised,
double blind, controlled trial was conducted in rural
Burkina Faso in the Nanoro Health and Demographic
Surveillance System area [17], situated 85 km from
Ouagadougou (Additional file 1). Two previous surveys
in Burkina Faso indicated a BV prevalence of approxi-
mately 6–8% [18, 19]. HIV prevalence is low and re-
ported as 1.2% among women aged 15–49 years and
0.76% among pregnant women [20]. Women were re-
cruited from 30 villages and individual and guardian
written consents were obtained. Healthy nulliparous,
non-pregnant women aged 15–24 years received either
weekly ferrous gluconate and folic acid (intervention), or
folic acid alone (control) as a directly observed therapy.
Participation continued for 18 months for women who
did not conceive or, if they became pregnant, they en-
tered the pregnant cohort. Weekly supplementation con-
tinued until a scheduled first antenatal visit (ANC1),
which was the trial primary end-point.
Non-pregnant cohort
At enrolment demographic data and medical/obstetric
histories were recorded and women were clinically ex-
amined. Height (nearest mm), weight (nearest 100 g),
and mid-upper arm circumference (mm; MUAC) were
measured in duplicate. A venous blood sample (5 mL)
was collected for later iron biomarker assessments. Two
self-taken swabs were requested for a BV slide and pH
measurement. Samples were not collected during men-
ses. Women symptomatic for T. vaginalis and BV were
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treated with single dose metronidazole (2 g orally), and
those symptomatic for C. albicans with miconazole
(200 mg intravaginally, daily for 3 days). All participants
received a single dose of albendazole (400 mg) and
praziquantel (1500–2400 mg according to height).
Participants were individually randomised to receive
either a capsule containing ferrous gluconate (60 mg)
and folic acid (2.8 mg), or an identical capsule contain-
ing folic acid alone (2.8 mg), as then recommended by
WHO [15]. This regimen was directly observed at
weekly visits and continued for up to 18 months, when
an end assessment (FIN) was completed and repeat vagi-
nal swabs for BV and vaginal pH were requested. At
FIN, duplicate swabs were additionally requested for
preparation of vaginal fluid eluates for microbiota and T.
vaginalis PCR assays. Swabs were kept cool until
returned to the laboratory within 2–4 hours. A venous
blood sample (5 mL) was obtained for iron biomarkers
and malaria microscopy.
Women were monitored for pregnancy at weekly visits
and symptoms of illness were recorded by a field worker.
Symptomatic participants were directed to attend a
health centre for free medical treatment for participant
care, as this was required for a safety trial. Health centre
staff recorded all visits, and a medically qualified re-
searcher collated information on symptoms, clinical
diagnoses and treatments. Pregnant women were
instructed to attend Nanoro hospital for ANC1.
Pregnant cohort
At ANC1 (primary endpoint), scheduled at 13–16 weeks’
gestation, a venous blood sample (5 mL) was obtained
for iron biomarkers and malaria microscopy, and self-
taken vaginal swabs requested as for the non-pregnant
cohort. An ultrasound examination was completed to
date gestational age. Symptomatic women were treated
for BV and T. vaginalis with metronidazole 500 mg or-
ally twice daily for 7 days, for C. albicans with intravagi-
nal miconazole 200 mg daily for 3 days, and for N.
gonorrhoeae and C. trachomatis with ceftriaxone 250 mg
intramuscularly once and amoxycillin 500 mg orally
thrice daily for 7 days for suspected cervical infection.
Women were encouraged to deliver at their closest
health centre. The study provided free obstetric care.
Laboratory procedures
Bacterial vaginosis
BV slides were fixed, Gram stained, air dried and for-
warded to the Microbiology Laboratories, Central Man-
chester University Hospital NHS Trust, UK, for Nugent
scoring [21]. Approximately 10% of slides, plus indeter-
minate slides, were read in duplicate. Nugent scores of
7–10 indicated BV, 4–6 intermediate, and 0–3 normal
flora. Gram stains were available for 80.5% of women at
enrolment, 76.5% at FIN, and 94.6% at ANC1, with no
differences between trial arms.
Vaginal eluates
Each tube containing a swab for vaginal eluate was proc-
essed on laboratory arrival when 5 mL of PBS was added to
the tube and shaken at high speed (5 minutes), before pip-
etting and freezing (–20 °C). Vaginal eluates were air
freighted on dry ice to the University of Northumbria, UK.
Malaria microscopy
Blood films were stained with Giemsa and read inde-
pendently by two qualified microscopists and, in the case
of discordant results, by a third reader.
Iron status
At the Nanoro Research Laboratories, ferritin, indicative
of iron stores, and serum transferrin receptor (sTfR), in-
dicative of functional iron deficit, were measured in du-
plicate by ELISA (Spectro Ferritin S-22 and TFC 94
Transferrin Receptor, RAMCO Laboratories Inc., Texas)
and C-reactive protein (CRP) by ELISA (EU59131, IBL
International, GMBH, Hamburg). Definitions of iron de-
ficiency were (1) adjusted ferritin (adjFE) allowing for in-
flammation, ferritin < 15 μg/L if CRP < 10 μg/mL, or
ferritin < 70 μg/L if CRP ≥ 10 μg/mL; or (2) a ratio of
sTfR μg/mL to log10 ferritin > 5.6, [22], which assesses
both stored and functional iron and is possibly less af-
fected by inflammation.
Microbiota/T. vaginalis qPCR
DNA was extracted from vaginal eluates using the
PowerLyzer Power Soil kit (MoBio, SD, USA) with the
following modifications. A 250-μL aliquot of vaginal elu-
ate was combined with 500 μL of bead solution added to
the bead tube and processed following the manufac-
turer’s instructions. DNA extraction negative controls
were processed for each kit and sequenced alongside test
samples. Bacterial profiling of the variable region 4 (V4)
of the 16S rRNA gene was performed by NU-OMICS
(Northumbria University) based on the Schloss wet-lab
MiSeq procedure [23], and T. vaginalis by qPCR [24]
(Additional file 2).
Statistical analysis
The sample size was determined from formal power cal-
culations for the malaria trial endpoints [25]. Analyses
excluded women who remained non-menarcheal
throughout the trial and any who became menarcheal
within 6 months of FIN when menses may have been ir-
regular. The primary analyses were comparisons of BV
(Nugent > 6) risk at ANC1 and at FIN (menarcheal) by
arm on an intention to treat basis using a binomial
model with a log link, and baseline infection and use of
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antibiotics in the 3 months prior to assessment as covar-
iates. Other infection markers were analysed similarly.
Nugent scoring gave a 3-level classification and each
level was compared to the remaining levels. Intention to
treat analyses of iron deficiency used a similar approach
with no covariates.
Associations between baseline infections and dichoto-
mised iron deficiency markers were similarly analysed,
but with no covariate for antibiotic use, as free study
prescriptions had not commenced. The analysis adjusted
for MUAC, a surrogate for nutritional status. Associa-
tions between baseline infection indicators and continu-
ous biomarkers followed similar binomial models, with
log-transformed values scaled by their standard devia-
tions to give comparable risk ratios across markers. The
P values for multiple markers were adjusted for multiple
testing using the false discovery rate method [26].
Receipt of antibiotics, antifungals and analgesics was
classified by clinical indication. Poisson regression
models were used to estimate incidence ratios and to
test for differences between arms, using number of visits
between enrolment and assessment as an exposure time
offset. Incidence rates are presented per 50 visits as this
approximated the mean number of visits prior to follow-
up assessment. For separate indications, P values were
adjusted using the false discovery rate approach.
The statistical methods for analysis and visualisation
of microbiota communities are described in Additional
file 2. Multinomial regression models were used to
identify if Community State Type (CST) was associated
with trial arm, pregnancy, iron deficiency or infection
markers.
Results
Participants
A total of 1959 nulliparous women were randomised
and 1954 were included in the intention to treat dataset
(Fig. 1). During follow-up, 478 (24.5%) women became
pregnant, with 1476 remaining non-pregnant; 315
(65.9%) were assessed at ANC1, with two-thirds of these
visits occurring at < 20 weeks’ gestation. Among the
non-pregnant cohort, defined as menarcheal and
followed up to 18 months, 877 (56.6%) women com-
pleted an end assessment survey (FIN). Women lost to
follow-up differed in some baseline characteristics (Add-
itional file 3: Table S1). Table 1 shows baseline partici-
pant characteristics, categorised by subsequent status in
constituting the pregnant or non-pregnant cohorts. Trial
arms were well balanced. In the intention to treat ana-
lysis, the median (interquartile range) number of directly
observed treatments as a percentage of the number of
weeks in the study was 79% (58–90%, n = 1954), with no
difference by trial arm. For the total sample, adolescents
(<20 years) comprised 93%. BV prevalence was 12.3%,
with 8.9% having intermediate flora. BV correlated with
MUAC (RR per cm 1.23; 95% CI 1.08–1.41, P = 0.003)
and BMI (RR per kg/m2 1.23; 95% CI 1.08–1.40, P =
0.002), but not with age (P = 0.82). Prevalence of vaginal
Fig. 1 Participant flow chart
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Table 1 Baseline characteristics by trial arm of participants who subsequently became pregnant or remained non-pregnant during
follow-up
Variable Pregnant cohort Non-pregnant cohort
Na Iron Control Na Iron Control
N = 258 N = 220 N = 766 N = 783
Sociodemographic
Age, years, mean (SD) 478 17.1 (1.7) 17.1 (1.7) 1549 16.7 (1.7) 16.7 (1.8)
Ethnic group, n (%)
Mossi 478 250 (96.9) 214 (97.3) 1548 730 (95.3) 757 (96.8)
Other 478 8 (3.1) 6 (2.7) 1548 36 (4.7) 25 (3.2)
Marital status
Married 478 22 (8.5) 15 (6.8) 1544 17 (2.2) 18 (2.3)
Never married 478 236 (91.5) 204 (92.7) 1544 748 (97.8) 760 (97.6)
Previously married 478 0 (0) 1 (0.5) 1544 0 (0) 1 (0.1)
Occupation,b n (%)
Student 478 60 (23.3) 51 (23.2) 1549 255 (33.3) 274 (35.0)
Trading 478 10 (3.9) 10 (4.5) 1549 24 (3.1) 21 (2.7)
Domestic labour 478 154 (59.7) 120 (54.5) 1549 401 (52.3) 407 (52.0)
Farming 478 130 (50.4) 101 (45.9) 1549 269 (35.1) 290 (37.0)
Other 478 3 (1.2) 3 (1.4) 1549 3 (0.4) 2 (0.3)
Education, n (%)
No schooling 477 176 (68.5) 142 (64.5) 1544 447 (58.6) 450 (57.6)
Primary 478 54 (20.9) 38 (17.3) 1549 168 (21.9) 169 (21.6)
Lower secondary 477 24 (9.3) 38 (17.3) 1544 144 (18.9) 153 (19.6)
Higher secondary 477 3 (1.2) 2 (0.9) 1544 4 (0.5) 9 (1.2)
Literate, n (%) 473 68 (26.7) 62 (28.4) 1530 278 (36.8) 297 (38.4)
Reproductive history and infections, n (%)
Menarcheal 478 241 (93.4) 203 (92.3) 1549 639 (83.4) 645 (82.4)
Menarche age, mean (SD) 443 14.9 (1.0) 14.8 (1.1) 1279 15 (1.0) 15.1 (1.1)
Ever had sex 478 98 (38) 82 (37.3) 1548 159 (20.8) 164 (21.0)
Uses contraception 478 54 (20.9) 51 (23.2) 1549 106 (13.8) 86 (11.0)
Uses condoms 478 53 (20.5) 50 (22.7) 1549 103 (13.4) 81 (10.3)
Nugent 7–10 391 33 (15.7) 23 (12.7) 1247 80 (13.0) 68 (10.8)
Nugent 4–6 391 17 (8.1) 11 (6.1) 1247 49 (8.0) 66 (10.5)
Nugent 0–3 391 160 (76.2) 147 (81.2) 1247 487 (79.1) 497 (78.8)
Vaginal discharge 478 3 (1.2) 4 (1.8) 1549 13 (1.7) 12 (1.5)
Vaginal pH≥ 4.5 394 119 (55.9) 84 (46.4) 1280 317 (50.3) 328 (50.5)
Nutrition and iron biomarkers, n (%)
Drinks alcohol 476 140 (54.5) 119 (54.3) 1549 372 (48.6) 380 (48.5)
BMI, kg/m2, mean (SD) 478 20.2 (1.8) 20.3 (2.1) 1549 19.7 (2.2) 19.6 (2.2)
MUAC, cm, mean (SD) 478 24.1 (1.8) 24.3 (2.2) 1549 23.6 (2.1) 23.6 (2.2)
Iron deficient (adjFE) 467 25 (10.0) 26 (12.0) 1528 84 (11.1) 100 (13.0)
Iron deficient (ratio sTfR/log ferritin) 470 52 (20.6) 55 (25.3) 1524 162 (21.4) 168 (21.9)
Adherence to treatment
DOT,c mean (SD) 478 70.3 (27.0) 71.4 (26.0) 1549 70.0 (27.8) 70.8 (26.3)
aTotal responders
bMore than one response allowed
cNumber of directly observed treatments as a percentage of the number of weeks from enrolment to assessment
adjFE adjusted ferritin, BMI body mass index, DOT directly observed treatment, MUAC mid-upper arm circumference, SD standard deviation, sTfR serum
transferrin receptor
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discharge was 1.6%. Vaginal pH ≥ 4.5 was recorded in
50.6%, with no difference between arms.
Infections and iron status at baseline assessment
Baseline prevalence of iron deficiency was lower using
the single iron biomarker adjFE than when using the
combined marker sTfR/log ferritin, but with either
marker, it did not differ by trial arm (Table 1). Preva-
lence of iron deficiency remained very similar by trial
arm using varying CRP cut-offs (5–25 μg/mL) (Add-
itional file 4b). Iron replete participants at baseline were
less likely to have normal vaginal flora (Nugent score 0–
3) (adjFE: P = 0.036; sTfR/log ferritin ratio: P = 0.255).
Vaginal discharge was reported by only a few women
but was less prevalent with iron repletion (adjFE: P =
0.03; sTfR/log ferritin ratio: P = 0.06) (Table 2). A sensi-
tivity analysis using alternative lower ferritin thresholds
of < 15 μg/L and CRP < 10 μg/mL, or < 30 μg/L and
CRP ≥ 10 μg/mL, for iron depletion adjusting for inflam-
mation was explored to assess whether a lower ferritin
cut-off significantly altered these associations (Add-
itional file 3: Table S2). Prevalence of vaginal discharge
remained significantly lower in iron replete women (P =
0.013), and normal vaginal flora remained significantly
less frequent in iron replete women (P = 0.028). High pH
was positively associated with plasma ferritin (adjFE) (P
= 0.015 adjusted for MUAC), but not the sTfR/log fer-
ritin ratio (P = 0.14) (Additional file 3: Table S3).
Lower genital tract infection in the pregnant cohort
ANC1
Prevalence of iron deficiency (adjFE) did not differ sig-
nificantly between trial arms (6.9% (iron) and 12.7%
(control); RR 0.54, 95% CI 0.27–1.1, P = 0.12) or based
on the sTfR/log ferritin ratio (11.1% (iron) and 12.7%
(control); RR 0.88, 95% CI 0.48–1.61, P = 0.73).
Prevalence was similar in iron and control arms
(Table 3) for BV (7.9% vs. 6.2%; RR 0.93, 95% CI 0.33–
2.56, P = 0.88), intermediate flora (11.2% vs. 13.0%; P =
0.86), T. vaginalis (15.6% vs. 10.1%; P = 0.17), and vaginal
discharge (8.6% vs. 7.9%; P = 0.85). Abnormal discharge
occurred in 24% of women with BV and 8% of those
with T. vaginalis.
Lower genital tract infection in the non-pregnant cohort
FIN
Prevalence of iron deficiency (adjFE) was 9.0% (iron) and
11.0% (control) (RR 0.82, 95% CI 0.55–1.22, P = 0.37)
and, based on sTfR/log ferritin ratio, it was 20.1% (iron)
and 21.2% (control) (RR 0.95, 95% CI 0.73–1.23, P =
0.74).
No prevalence difference was observed for BV (13.5%
iron vs. 12.1% control, RR 0.86, 95% CI 0.56–1.34, P =
0.51), intermediate flora (10.3% vs. 7.9%, P = 0.47), or T.
vaginalis (5.6% vs. 4.2%, P = 0.43) (Table 3). Vaginal dis-
charge was more frequent in iron-supplemented women
(11.5% vs. 6.9%, P = 0.026). This difference would be
Table 2 Baseline host iron status using two definitions of iron deficiency and infection markers (n = 1673, excluding 281 non-
menarcheal)
Infection N Replete (%) Deficient (%) Unadjusted Adjusteda
RR (95% CI) P valueb Nc RR (95% CI) P value
Adjusted ferritin
BVd 1347 0.127 1326 0.032
Nugent 7–10e 1347 142/1151 (12.3) 15/175 (8.6) 1.44 (0.87–2.39) 0.168 1326 1.53 (0.92–2.54) 0.104
Nugent 4–6e 1347 108/1151 (9.4) 11/175 (6.3) 1.49 (0.82–2.72) 0.203 1326 1.47 (0.81–2.68) 0.210
Nugent 0–3e 1347 901/1151 (78.3) 149/175 (85.1) 0.92 (0.86–0.99) 0.036 1326 0.92 (0.86–0.98) 0.016
Vaginal discharge 1673 21/1430 (1.5) 8/214 (3.7) 0.39 (0.18–0.88) 0.044 1644 0.41 (0.18–0.92) 0.030
pH≥ 4.5 1371 608/1166 (52.1) 86/183 (47.0) 1.11 (0.94–1.31) 0.204 1349 1.11 (0.94–1.30) 0.222
sTfR/log ferritin ratio > 5.6
BVd 1347 0.513 1324 0.224
Nugent 7–10e 1347 127/1030 (12.3) 30/294 (10.2) 1.21 (0.83–1.76) 0.358 1324 1.25 (0.86–1.83) 0.239
Nugent 4–6e 1347 95/1030 (9.2) 24/294 (8.2) 1.13 (0.74–1.73) 0.644 1324 1.12 (0.73–1.71) 0.619
Nugent 0–3e 1347 808/1030 (78.4) 240/294 (81.6) 0.96 (0.90–1.02) 0.255 1324 0.96 (0.90–1.02) 0.231
Vaginal discharge 1673 18/1270 (1.4) 11/372 (3.0) 0.48 (0.23–1.01) 0.070 1642 0.49 (0.23–1.04) 0.062
pH≥ 4.5 1371 551/1044 (52.8) 144/303 (47.5) 1.11 (0.97–1.27) 0.117 1347 1.11 (0.97–1.26) 0.126
aAdjusted for MUAC
bFishers Exact Test
cNumber of observations in adjusted analysis
dGlobal test (Fishers/ordinal regression) for BV as 3-category outcome
eEach group compared to both other groups
BV bacterial vaginosis, sTfR serum transferrin receptor
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considered non-significant allowing for the number of
secondary outcomes tested. Abnormal discharge oc-
curred in 9% of those with BV and 18% with T.
vaginalis.
Comparison of non-pregnant and pregnant cohorts
Cross-sectional BV prevalence was higher in non-
pregnant women at FIN (12.8%) than at ANC1 (7.0%)
(RR 1.8, 95% CI 1.2–2.9, P = 0.011, adjusted for antibiotic
use), but T. vaginalis prevalence was lower (4.9%) (RR
0.38, 95% CI 0.24–0.59, P < 0.001). P. falciparum preva-
lence was 54% at ANC1 and 41% at FIN, despite free ac-
cess to anti-malarial treatments.
Antibiotic courses
The number of antibiotic courses (excluding anti-
malarials) provided to the non-pregnant cohort was
higher in women receiving iron supplements (P = 0.014)
(Table 4). These also received more anti-fungal treat-
ments (P = 0.014) and analgesics (P = 0.008). BV and T.
vaginalis were mostly asymptomatic and, as these infec-
tions were unlikely to account for the high proportion of
women receiving antibiotics, all indications for antibiotic
prescription at Health Centres were assessed (Table 5).
The most frequent indications were respiratory illness,
gastrointestinal, reproductive tract and local infections.
Gastrointestinal infections were treated more frequently
in iron-supplemented women (P = 0.005, allowing for
the multiple indications tested) (Table 5). With far fewer
events, no significant differences were detected in the
pregnant cohort at ANC1 (Additional file 3: Table S4).
Vaginal microbiota
Figure 2 demonstrates the distribution of the top 20 taxa
for all samples combined by trial arm, study visit and BV
infection. Three CSTs typified this population, corre-
sponding to CST I (40.4%), III (24.6%) and IV (35%),
dominated by Lactobacillus crispatus, Lactobacillus iners
and a mixed community with reduced lactobacilli, re-
spectively. CST IV was more frequent in the non-
pregnant cohort at FIN than pregnant women at ANC1
(P < 0.001). CST IV was associated with BV (P < 0.001)
and T. vaginalis (P < 0.001) (Table 6). No differences
were observed in CST IV frequency or alpha- and beta-
diversity, by trial arm, or host iron status, in pregnant or
non-pregnant cohorts (Additional file 4c). Iron replete
women at ANC1 and FIN had non-significantly higher
Shannon diversity. CST frequencies did not differ signifi-
cantly from earlier results using the lower ferritin
threshold (Additional file 3: Table S5).
Discussion
In this young population, reported sexual activity was
low at recruitment but its commencement carried a sub-
stantial risk of immediate pregnancy, a sexually trans-
mitted infection (T. vaginalis), an unstable microbiota
and malaria, which was more frequent in primigravidae.
Evidence on effects of intermittent iron supplementation
on infectious disease outcomes is scarce and unclear,
Table 3 Lower genital tract infection indicators in pregnant (ANC1) and non-pregnant (FIN) cohorts by trial arm
Assessment Infection marker N Trial arm Unadjusted Adjusteda
Iron (%) Control (%) RR (95% CI) P valueb Nc RR (95% CI) P valuec
Pregnant Bacterial vaginosisd 298 0.776 245 0.704
ANC1 Nugent 7–10e 298 12/152 (7.9) 9/146 (6.2) 1.28 (0.56–2.95) 0.653 245 0.93 (0.33–2.56) 0.881
N = 315 Nugent 4–6e 298 17/152 (11.2) 19/146 (13.0) 0.86 (0.47–1.59) 0.723 245 0.94 (0.47–1.88) 0.858
Nugent 0–3e 298 123/152 (80.9) 118/146 (80.8) 1.00 (0.90–1.12) 1 245 1.03 (0.91–1.15) 0.665
T. vaginalisf 286 23/147 (15.6) 14/139 (10.1) 1.55 (0.83–2.90) 0.217 286 1.55 (0.83–2.90) 0.168
Vaginal discharge 315 14/163 (8.6) 12/152 (7.9) 1.09 (0.52–2.28) 0.841 315 1.08 (0.51–2.25) 0.846
pH≥ 4.5 309 92/158 (58.2) 86/151 (57.0) 1.02 (0.84–1.24) 0.908 260 1.06 (0.86–1.31) 0.555
Non-pregnant Bacterial vaginosisd 671 0.588 546 0.676
FINf Nugent 7–10e 671 46/341 (13.5) 40/330 (12.1) 1.11 (0.75–1.65) 0.645 546 0.86 (0.56–1.34) 0.509
N = 877 Nugent 4–6e 671 35/341 (10.3) 26/330 (7.9) 1.30 (0.80–2.11) 0.347 546 1.21 (0.72–2.03) 0.467
Nugent 0–3e 671 260/341 (76.2) 264/330 (80.0) 0.95 (0.88–1.03) 0.263 546 0.99 (0.90–1.08) 0.806
T. vaginalisf 716 20/360 (5.6) 15/356 (4.2) 1.32 (0.69–2.53) 0.489 716 1.30 (0.67–2.50) 0.432
Vaginal discharge 874 49/425 (11.5) 31/449 (6.9) 1.67 (1.09–2.57) 0.019 874 1.63 (1.06–2.51) 0.026
aAdjusted for baseline infection and use of antibiotics in previous 3 months
bFishers exact test
cLogistic regression
dEach group compared to both other groups
eExcludes those less than 6 months post menarcheal
fBaseline not available
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with few studies and small sample sizes [15]. This rando-
mised, controlled, double blind trial found no evidence
that 60 mg iron/2.8 mg folic acid supplements offered
weekly, increased the risk of BV, T. vaginalis, or CST IV
microbiota in either the pregnant or non-pregnant cohort.
A two-fold increased use of antibiotics for treatment of
gastrointestinal infections, with increased use of anti-
fungals for lower genital infection in the non-pregnant
iron supplemented cohort, raises new concerns about the
safety of weekly iron supplements for young women. Nu-
tritional status, reflected by MUAC, was an effect modifier
for BV infection. This result adds to a growing body of
evidence of an association between diet and BV, for which
there is currently no clear explanation [27].
A major strength of this study was its large cohort of
non-pregnant peri-menarcheal adolescents, as well as a
concurrent pregnancy cohort [16]. Some loss to follow-
up occurred due to movement outside the study area
following marriage, unwanted pregnancy or, if unmar-
ried, working for relatives living elsewhere. Trial partici-
pants were young, nulliparous girls, with low prevalence
of iron deficiency at recruitment. Accurate estimation of
Table 4 Health Centre treatment courses prescribed to pregnant and non-pregnant cohorts by trial arm from enrolment to ANC1
(pregnant) or FIN (non-pregnant)
Treatment Number of treatments Mean treatments per person Mean treatments per 50 visitsa Incidence ratiob (95% CI) P value
Iron Control Iron Control Iron Control
Pregnant n = 163 n = 152 Visits = 6907 Visits = 6235
Antibiotics 92 73 0.564 0.480 0.666 0.585 1.14 (0.84–1.55) 0.411
Anti-fungalsc 16 15 0.098 0.099 0.116 0.120 0.96 (0.47–1.95) 0.916
Analgesics 107 107 0.656 0.704 0.775 0.858 0.90 (0.69–1.18) 0.454
Non-pregnant n = 426 n = 451 Visits =26473 Visits =27633
Antibiotics 331 284 0.777 0.630 0.625 0.514 1.22 (1.04–1.43) 0.015
Anti-fungalsc 39 21 0.092 0.047 0.074 0.038 1.94 (1.14–3.30) 0.014
Analgesics 481 421 1.129 0.933 0.908 0.762 1.19 (1.05–1.36) 0.008
aMean number of visits: 42 in pregnant and 63 in non-pregnant
bIncidence ratio was computed using Poisson regression with the number of visits as the exposure period
cMore than 90% of vaginal pessaries prescribed for genital tract infections
Table 5 Mean number of health centre antibiotic treatments in non-pregnant cohort by infection diagnosis and trial arm from en-
rolment to FIN
Infection indication Iron Control Iron per 50 visits
n = 26,473
Control per 50 visits
n = 27,633
Incidence ratioa
(95% CI)
P value PFDRb
Malariac 41 28 0.077 0.051 1.53 (0.94–2.47) 0.084 0.278
Respiratory 75 87 0.142 0.157 0.90 (0.66–1.23) 0.503 0.719
Locald 75 57 0.142 0.103 1.37 (0.97–1.94) 0.071 0.278
Gastrointestinale 62 30 0.117 0.054 2.16 (1.39–3.34) <0.001 0.005
Urinary tractf 10 9 0.019 0.016 1.16 (0.47–2.86) 0.747 0.934
STIg 13 7 0.025 0.013 1.94 (0.77–4.86) 0.158 0.292
Genitalh 15 16 0.028 0.029 0.98 (0.48–1.98) 0.952 0.993
Dental 11 5 0.021 0.009 2.30 (0.80–6.62) 0.123 0.292
Meningitis 0 3 0 0.005 0 (NA) 0.993 0.993
Miscellaneousi 29 42 0.055 0.076 0.72 (0.45–1.16) 0.175 0.292
aIncidence ratio was computed using Poisson regression with the number of visits as the exposure period
bP value adjusted for multiple testing using false discovery rate method [26]
cAntibiotics in addition to anti-malarial treatment
dNon-enteric and non-respiratory, includes ear, skin, ophthalmic, abscess, wounds, local trauma, sinusitis, mastoiditis, keloid, scalp ringworm
eDysentry, typhoid, enteritis, intestinal parasitosis, gastric ulcer, gastroenteritis, diarrhoea and abdominal pain, vomiting and abdominal pain, amoebiasis,
colopathy, sub-occlusion
fCystitis, dysuria
gIncludes syphilis, trichomoniasis
hUpper or lower genital infection
iItching, colic, headache, generalised or localised pain, fever, vomiting only, anaemia, anxiety, neuralgia, spasms, urticarial, plus non-infectious specific diagnoses:
cancers, fertility problems, angina, self-medication, allergy, burns, renal stones, contraception, thyroid and cardiac diseases, epilepsy, filariasis, foreign body, venom-
ous bites, fractures, migraine, HIV, varicella, mumps, prophylactic and non-classifiable: includes three uncertain descriptors, or absent statement
PFDR positive false discovery rate, STI sexually transmitted infection
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iron deficiency prevalence is influenced by effects of inflam-
mation on indices such as ferritin. A recent meta-analysis
in women of reproductive age experiencing inflammation
estimated the difference of depleted iron stores between ad-
justed and unadjusted ferritin values as 2–8 median per-
centage points, dependent on the adjustment method [28].
We used a high ferritin cut-off of < 70 μg/L for iron defi-
ciency in women with CRP ≥ 10 μg/mL, allowing for in-
flammation, as well as the lower cut-off < 15 μg/L with
CRP < 10 μg/L to include those without inflammation. CRP
concentration increases in early pregnancy, which was ac-
commodated by using the CRP < 10 μg/L cut-off. Although
prevalence of iron deficiency in absolute terms varied ac-
cording to the CRP cut-off used, sensitivity analyses showed
that trends and trial arm differences in iron deficiency were
similar irrespective of CRP level. We additionally used the
sTfR/log10 ferritin ratio > 5.6, which is derived from an
intermediate ferritin cut-off of < 30 μg/L [22]. We consid-
ered this provided a reasonable estimate of iron deficiency.
Sensitivity analysis of alternative ferritin thresholds for de-
fining iron deficiency, adjusting for inflammation, gave very
similar results.
Despite good supplementation adherence over an
18 month period, facilitated by weekly direct observa-
tion, there was no significant improvement in systemic
iron biomarkers. The absence of an association between
iron supplementation and BV or T. vaginalis prevalence
could relate to the lack of intervention efficacy in redu-
cing iron deficiency. At baseline, iron-replete partici-
pants were less likely to have normal vaginal flora, which
suggests host iron status is reflected in the mucosa. Fol-
lowing supplementation, an increased prescription for
fungal infections was also observed inferring an iron-
fungal infection interaction [29]. Antibiotics used for
treatment of enteric infections may have altered lower
genital tract bacterial profiles. Cessation of menses with
pregnancy would also reduce iron availability to haem-
utilising pathogens.
Chronic inflammation from malaria, which was fre-
quent, as well as other infections, would increase hepci-
din release, restricting iron absorption. In Beninese
women with afebrile P. falciparum parasitaemia, dietary
iron absorption was reduced by approximately 40% with
infection [30]. In the non-pregnant cohort, a signifi-
cantly higher number of antibiotic-treated gastrointes-
tinal infections – predominantly diagnosed as dysentery,
typhoid, and intestinal parasitosis – occurred in supple-
mented women, possibly related to unabsorbed iron be-
coming available to colonic gut microbiota [30].
Although some misclassification of infection categories
would arise due to a lack of laboratory confirmation, this
should not alter findings by trial arm. Increased gut in-
flammation and pathogenicity following iron supplemen-
tation, or fortification, is reported in children exposed to
high infection pressure in Ghana [31] and Kenya [32],
and increased risk of bloody dysentery and respiratory
infection in Pakistan [33]. This is the first report in young
women to show increased enteric symptoms requiring
antibiotic treatments following iron supplementation.
Concurrent infection with non-typhi salmonella and P.
falciparum should be considered [34]. Increased use of
antifungal prescriptions in the iron-supplemented non-
pregnant cohort is of interest because, both in the gut and
vaginal mucosa, C. albicans is a normal commensal, com-
peting with other organisms for nutrients, and increased
fungal virulence due to iron malabsorption could be
Fig. 2 Heatmap showing distribution of the 20 most abundant taxa across all samples with coloured bars showing trial arm, study visit and
BV infection
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anticipated. In addition, disruption to normal bacterial gut
populations due to tetracycline treatment can result in
candida overgrowth, reducing colonisation resistance [35].
The intestinal tract is considered as a reservoir of infection
leading to recurrent vaginal candidiasis based on the cor-
respondence between vaginal and stool samples [36].
Self-taken vaginal swabs proved acceptable, providing
samples for gram stains, vaginal eluates and microbiota
assays. The absence of differences in microbiota CST
categories by trial arm is consistent with no supplemen-
tation effect on BV or T. vaginalis. BV was associated
with CST IV, and both had lower prevalence in pregnant
than non-pregnant women [37]. This pregnancy differ-
ence is probably related to hormonal factors [38], al-
though we cannot exclude the possibility that it is
mediated by differences in other characteristics between
those who became pregnant and those that did not. In
marked contrast, T. vaginalis prevalence, also associated
Table 6 Community state type distribution in pregnant and non-pregnant (menarcheal) cohorts by trial arm, iron deficiency and in-
fection status
Variable Visit Group n CST I
n (%)
CST III
n (%)
CST IV
n (%)
P valuea
Trial arm ANC1 Iron 144 70 (48.6) 39 (27.1) 35 (24.3) 0.518
Control 136 61 (44.9) 45 (33.1) 30 (22.1)
FINb Iron 349 121 (34.7) 88 (25.2) 140 (40.1) 0.113
Control 341 140 (1.1) 66 (19.4) 135 (9.6)
Iron deficiency, Adjusted ferritin ANC1 No 249 118 (47.4) 75 (30.1) 56 (22.5) 0.57
Yes 27 10 (37.0) 9 (33.3) 8 (29.6)
FINb No 620 237 (38.2) 140 (22.6) 243 (39.2) 0.281
Yes 65 20 (30.8) 13 (20.0) 32 (49.2)
Ratio sTfR/log ferritin ANC1 No 247 120 (48.6) 74 (30.0) 53 (21.5) 0.216
Yes 32 11 (34.4) 10 (31.2) 11 (34.4)
FINb No 544 205 (37.7) 124 (22.8) 215 (39.5) 0.81
Yes 140 52 (37.1) 29 (20.7) 59 (42.1)
Nugent scorec ANC1 7-10 15 0 (0) 1 (6.7) 14 (93.3) <0.001
4-6 31 7 (22.6) 6 (19.4) 18 (58.1) <0.001
0-3 221 116 (52.5) 74 (33.5) 31 (14.0) <0.001
FINb 7-10 80 2 (2.5) 6 (7.5) 72 (90.0) <0.001
4-6 60 11 (18.3) 6 (10.0) 43 (71.7) <0.001
0-3 501 232 (46.3) 132 (26.3) 137 (27.3) <0.001
T. vaginalis ANC1 No 243 121 (49.8) 73 (30.0) 49 (20.2) 0.006
Yes 37 10 (27.0) 11 (29.7) 16 (43.2)
FINb No 655 260 (39.7) 149 (22.7) 246 (37.6) <0.001
Yes 35 1 (2.9) 5 (14.3) 29 (82.9)
High pH≥ 4.5 ANC1 No 123 73 (59.3) 37 (30.1) 13 (10.6) <0.001
Yes 153 58 (37.9) 45 (29.4) 50 (32.7)
Vaginal discharge ANC1 No 260 122 (46.9) 80 (30.8) 58 (22.3) 0.268
Yes 20 9 (4.5) 4 (20.0) 7 (35.0)
FINb No 618 232 (37.5) 144 (23.3) 242 (39.2) 0.205
Yes 69 28 (40.6) 10 (14.5) 31 (44.9)
Antibiotics within previous three months ANC1 No 252 118 (46.8) 73 (29.0) 61 (24.2) NA
Yes 28 13 (46.4) 11 (39.3) 4 (14.3)
FINb No 616 236 (38.3) 136 (22.1) 244 (39.6) NA
Yes 74 25 (33.8) 18 (24.3) 31 (41.9)
aP value for association between status and CST from a multinomial regression model adjusting for antibiotic use in the 3 months prior to assessment
bMenarcheal women only
cEach Nugent group compared to the other two. BV corresponds to Nugent score 7–10
ANC1 first antenatal visit, CST community state type, FIN end assessment, sTfR serum transferrin receptor
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with CST IV, was three-fold higher at ANC1 compared
to non-pregnant women at FIN, probably due to more
regular sexual activity with male partners untreated for
this sexually transmitted infection. Interactions between
BV and T. vaginalis are poorly understood [39] but,
under experimental conditions, T. vaginalis is associated
with reduced populations of Lactobacillus spp, but not
BV spp [40]. Co-infection in early pregnancy may hinder
transition to stable microbiome communities, such as
CST I, which is associated with better pregnancy out-
comes [41]. Clinical outcomes may depend on initial
host iron status, as experimental studies have shown al-
tered inflammatory responses, higher abundance of Bifi-
dobacteriaceae and Lactobacillaceae, and prolonged
intestinal nematode survival in animals receiving iron-
deficient diets [42].
At baseline, elevated vaginal pH values (≥4.5) were ob-
served in iron-replete participants and were positively
associated with plasma ferritin (P = 0.015). High vaginal
pH may be attributable to normal pubertal changes [43],
young age, irregular menses [44], and factors impacting
on lactobacilli or other lactic acid producing microbes
[45], but also to genital tract infection. The reason in
this study for the significant association of high pH and
more disturbed flora in adolescents with better iron
stores before supplementation is unknown and warrants
further investigation.
Conclusions
There was no evidence that weekly iron increased the
risk of BV or T. vaginalis infections, but the intervention
was considered poorly absorbed as systemic iron bio-
markers were not significantly changed. Iron supplemen-
tation did result in more gastrointestinal morbidity,
leading to increased antibiotic prescription and genital
tract infection requiring antifungal treatments in the
non-pregnant cohort. This is a concern since recently
revised WHO recommendations are shifting in favour of
providing intermittent daily iron [46]. A daily regime
could be more likely to exacerbate gut microbes and/or
increase antibiotic/antifungal prescriptions. Since mal-
aria is the most likely cause of iron malabsorption in the
gut, iron supplementation studies in malaria endemic
areas need to profile enteric and vaginal infections, as
well as antibiotic use.
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